Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis

Background: Cabozantinib, a multiple kinase inhibitor, was recently approved for patients with previously treated unresectable hepatocellular carcinoma (uHCC). We investigated the real-world safety and efficacy profiles of cabozantinib. Methods: This multicenter retrospective study included 110 pati...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Yeong Hak Bang, Choong-kun Lee, Changhoon Yoo, Hong Jae Chon, Moonki Hong, Beodeul Kang, Hyung-Don Kim, Sook Ryun Park, Won-Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Min-Hee Ryu, Baek-Yeol Ryoo
Формат: Artigo
Язык:Inglês
Опубликовано: SAGE Publishing 2022-05-01
Серии:Therapeutic Advances in Medical Oncology
Online-ссылка:https://doi.org/10.1177/17588359221097934
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы